Stock Analysis on Net

Elevance Health Inc. (NYSE:ELV)

Income Statement
Quarterly Data

The income statement presents information on the financial results of a company business activities over a period of time. The income statement communicates how much revenue the company generated during a period and what cost it incurred in connection with generating that revenue.

Elevance Health Inc., consolidated income statement (quarterly data)

US$ in millions

Microsoft Excel
3 months ended: Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Premiums 36,809 35,416 35,696 35,138 35,259 36,589 35,868 33,646 33,722 33,076 32,785 30,769 30,395 28,533 27,676 27,108 26,392 25,092 25,517 24,036 23,793 23,501 22,843
Product revenue 5,887 5,530 4,499 5,394 5,177 4,859 4,022 4,137 3,972 3,568 3,301 3,525 3,353 3,042 2,737 2,899 2,598 2,543 2,344 1,500 1,116 144
Service fees 2,023 2,277 2,078 1,922 2,044 1,929 2,008 1,884 1,931 1,838 1,800 1,724 1,800 1,704 1,685 1,526 1,659 1,543 1,587 1,596 1,535 1,532 1,545
Operating revenue 44,719 43,223 42,273 42,454 42,480 43,377 41,898 39,667 39,625 38,482 37,886 36,018 35,548 33,279 32,098 31,533 30,649 29,178 29,448 27,132 26,444 25,177 24,388
Benefit expense (32,949) (30,572) (30,546) (31,334) (30,606) (31,604) (30,786) (30,091) (29,404) (28,777) (28,215) (27,538) (26,645) (24,763) (23,699) (24,088) (22,921) (19,547) (21,489) (21,383) (20,753) (20,368) (19,282)
Cost of products sold (5,093) (4,820) (3,825) (4,837) (4,648) (4,327) (3,481) (3,646) (3,437) (3,069) (2,883) (3,070) (2,898) (2,614) (2,313) (2,522) (2,222) (2,225) (1,984) (1,149) (745) (98)
Cost of operating revenue (38,042) (35,392) (34,371) (36,171) (35,254) (35,931) (34,267) (33,737) (32,841) (31,846) (31,098) (30,608) (29,543) (27,377) (26,012) (26,610) (25,143) (21,772) (23,473) (22,532) (21,498) (20,466) (19,282)
Gross profit 6,677 7,831 7,902 6,283 7,226 7,446 7,631 5,930 6,784 6,636 6,788 5,410 6,005 5,902 6,086 4,923 5,506 7,406 5,975 4,600 4,946 4,711 5,106
Operating expense (5,269) (5,066) (4,886) (4,999) (5,470) (4,818) (4,800) (4,562) (4,514) (4,269) (4,341) (4,222) (3,946) (3,821) (3,925) (4,318) (5,305) (4,046) (3,781) (3,502) (3,418) (3,278) (3,166)
Amortization of other intangible assets (122) (162) (116) (217) (212) (221) (235) (247) (225) (166) (129) (135) (136) (90) (80) (92) (93) (93) (83) (82) (84) (85) (87)
Operating income 1,286 2,603 2,900 1,067 1,544 2,407 2,596 1,121 2,045 2,201 2,318 1,053 1,923 1,991 2,081 513 108 3,267 2,111 1,016 1,444 1,348 1,853
Net investment income 551 508 465 529 493 416 387 373 371 381 360 352 335 400 291 286 280 57 254 268 242 285 210
Net gains (losses) on financial instruments (125) (85) (161) (336) (124) (121) (113) (111) (57) (231) (151) 211 (61) 172 (4) 5 229 29 (81) 7 (12) 4 68
Gain (loss) on sale of business (39) 240
Interest expense (300) (280) (265) (259) (259) (261) (251) (229) (213) (208) (201) (200) (201) (205) (192) (191) (198) (201) (194) (190) (185) (184) (187)
Gain (loss) on extinguishment of debt (16) (5) (2) (30) (3) (1) (3) 1
Income before income tax expense 1,373 2,986 2,939 1,001 1,654 2,441 2,619 1,154 2,146 2,143 2,326 1,400 1,996 2,353 2,176 611 389 3,149 2,089 1,098 1,489 1,453 1,945
Income tax expense (365) (685) (690) (170) (354) (585) (615) (193) (533) (493) (531) (275) (494) (552) (509) (60) (167) (873) (566) (164) (306) (314) (394)
Net income 1,008 2,301 2,249 831 1,300 1,856 2,004 961 1,613 1,650 1,795 1,125 1,502 1,801 1,667 551 222 2,276 1,523 934 1,183 1,139 1,551
Net (income) loss attributable to noncontrolling interests 8 (1) (3) 25 (11) (3) (15) (12) 5 3 10 12 7 (8) (2)
Shareholders’ net income 1,016 2,300 2,246 856 1,289 1,853 1,989 949 1,618 1,653 1,805 1,137 1,509 1,793 1,665 551 222 2,276 1,523 934 1,183 1,139 1,551

Based on: 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

Income statement item Description The company
Operating revenue Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. Elevance Health Inc. operating revenue increased from Q1 2024 to Q2 2024 and from Q2 2024 to Q3 2024.
Operating income The net result for the period of deducting operating expenses from operating revenues. Elevance Health Inc. operating income decreased from Q1 2024 to Q2 2024 and from Q2 2024 to Q3 2024.
Income before income tax expense Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Elevance Health Inc. income before income tax expense increased from Q1 2024 to Q2 2024 but then decreased significantly from Q2 2024 to Q3 2024.
Shareholders’ net income The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Elevance Health Inc. shareholders’ net income increased from Q1 2024 to Q2 2024 but then decreased significantly from Q2 2024 to Q3 2024.